There are some weak points on this data.

This is a small scale trial (25 patients), non blinded and non randomized (it means it can be strongly biased by investigators and you have nothing to compare like "standard of care").  
The picture above isn't clear since what they mean by "no treatment"? Who are these patients? how they select these parameters/patients with "no treatment"? (according to clinical trial register - there is no comparator, no placebo, no standard of care, only IMP investigational medical product).
We don't know when these patients received the treatment (we don't know the really health condition of these subjects at screening).
(according to clinical trial register - Women and men with documented respiratory infection with Coronavirus SARS CoV 2)

Despite this product can sound interesting at first sight (like all treatment when we start a clinical trial ) I guess is a bit early to claim any real effect, and even it should be evaluated in a large scale with strong scientific criteria (randomization, double blind etc)

(just a note about preprint, they are publishing in a "small" journal, Impact Factor: 4.615 (NEJM Impact factor: 70.67))